急性丙型肝炎的诊断及治疗

赵宁; 李智伟

doi:10.3969/j.issn.1001-5256.2014.06.003

急性丙型肝炎的诊断及治疗

DOI: 10.3969/j.issn.1001-5256.2014.06.003

赵宁,
李智伟

中国医科大学附属盛京医院感染科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 3013
- HTML全文浏览量: 8
- PDF下载量: 768
- 被引次数: 0
出版历程
- 收稿日期: 2013-12-24
- 出版日期: 2014-06-20

Diagnosis and treatment of acute hepatitis C

Department of Infectious Disease, Shengjing Hospital, China Medical University

摘要

摘要: 急性丙型肝炎是由HCV感染引起的一种急性传染病。对急性丙型肝炎患者给予正确的诊断及合理的治疗,对阻止疾病进展尤为重要。对近年来有关急性丙型肝炎方面的研究进行回顾,急性丙型肝炎的流行病学、临床特征、诊断及治疗进展进行了综述,为临床医生更好的认识急性丙型肝炎,采取科学合理的诊疗措施提供依据。
- 丙型肝炎 /
- 诊断 /
- 治疗 /
- 综述
Abstract: Acute hepatitis C is an acute infectious disease caused by hepatitis C virus. Accurate diagnosis and proper treatment are very important for preventing the progression of this disease. Recent research advances in acute hepatitis C, including the epidemiological and clinical features, diagnosis, and treatment of acute hepatitis C, are reviewed, in order to provide a basis for better understanding of acute hepatitis C and proper diagnosis and treatment of this disease among clinicians.
- hepatitis C /
- diagnosis /
- therapy /
- review

HTML全文

参考文献(34)

[1] GHANY MG, STRADER DB, THOMAS DL, et al.Diagnosis, management, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.

[2]SHEPARD CW, FINELLI L, ALTER MJ.Global epidemiology of hepatitis C virus infection[J].Lancet Infect Dis, 2005, 5 (9) :558-567.

[3]MOSLEY J, OPERSKALSKI E, TOBLER L, et al.Viral and host factors in early hepatitis C virus infection[J].Hepatology, 2005, 42 (1) :86-92.

[4]BERTOLETTI A, FERRARI C.Kinetics of the immune response during HBV and HCV infection[J].Hepatology, 2003, 38 (1) :4-13.

[5]DETERDNG K, WIEGAND J, GRUNER N, et al.The German Hep-Net acute hepatitis C cohort:impact of viral and host factors on the initial presentation of acute hepatitis C virus infection[J].Z Gastroenterol, 2009, 47 (6) :531-540.

[6]ORLAND J, WRIGHT T, COOPER S.Acute hepatitis C[J].Hepatology, 2001, 33 (2) :321-327.

[7]LOOMBA R, RIVERA M, MCBURNEY R, et al.The natural history of acute hepatitis C:clinical presentation, laboratory findings and treatment outcomes[J].Aliment Pharmacol Ther, 2011, 33 (5) :559-565.

[8]SANTANTONIO T, WIEGAND J, GERLACH JT.Acute hepatitis C:current status and remaining challenges[J].J Hepatol, 2008, 49 (4) :625-633.

[9]RAO H, SUN D, JIANG D, et al.IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection[J].J Viral Hepat, 2012, 19 (3) :173-181.

[10]RERKSUPPAPHOL S, HARDIKAR W, DORE G.Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children[J].J Gastroenterol Hepatol, 2004, 19 (12) :1357-1362.

[11]MICALLEF J, KALDOR J, DORE G.Spontaneous viral clearance following acute hepatitis C infection:a systematic review of longitudinal studies[J].J Viral Hepat, 2006, 13 (1) :34-41.

[12]GERLACH JT, DIEPOLDER HM, ZACHOVAL R, et al.Acute hepatitis C:high rate of both spontaneous and treatment-induced viral clearance[J].Gastroenterology, 2003, 125 (1) :80-88.

[13]WANG C, KRANTZ E, KLARQUIST J, et al.Acute hepatitis C in a contemporary US cohort:modes of acquisition and factors influencing viral clearance[J].J Infect Dis, 2007, 196 (10) :1474-1482.

[14]LEHMANN M, MEYER MF, MONAZAHIAN M, et al.High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection[J].J Med Virol, 2004, 73 (6) :387-391.

[15]REHERMANN B.Hepatitis C virus versus innate and adaptive immune responses:a tale of coevolution and coexistence[J].J Clin Inves, 2009, 119 (7) :1745-1754.

[16]STEGMANN KA, BJORKSTROM NK, CIESEK S, et al.Interferon alpha-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1[J].J Infect Dis, 2012, 205 (9) :1351-1362.

[17]POST J, RATNARAJAH S, LLOYD AR.Immunological determinants of the outcomes from primary hepatitis C infection[J].Cell Mol Life Sci, 2009, 66 (5) :733-756.

[18]SCHLAPHOFF V, LUNEMANN S, SUNEETHA PV, et al.Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD81 T cells[J].PLoS Pathog, 2011, 7 (5) :e1002045.

[19] GE D, FELLAY J, THOMPSON A, et al.Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance[J].Nature, 2009, 461 (7262) :399-401.

[20]BEINHARDT S, ABERLE JH, STRSEEER M, et al.Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection[J].Gastroenterology, 2012, 142 (1) :78-85.

[21] THOMAS D, THIO C, MARTIN M, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.

[22]COX A, NETSKI D, MOSBRUGER T, et al.Prospective evaluation of community-acquired acute-phase hepatitis C virus infection[J].Clin Infect Dis, 2005, 40 (7) :951-958.

[23]MCGOERRN BH, BRICH CE, BOWEN MJ, et al.Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria[J].Clin Infect Dis, 2009, 49 (7) :1051-1060.

[24]TRBUSEK J.Contribution of HCV core antigen testing in HCV diagnosis by test from the company Abbott laboratories[J].Epidemiol Mikrobiol Imunol, 2009, 58 (4) :207-208.

[25]PETERSON J, GREEN G, IIDA K, et al.Detection of hepatitis C core antigen in the antibody negative“window”phase of hepatitis C infection[J].Vox Sang, 2000, 78 (2) :80-85.

[26]GU S, LIU J, ZHANG H, et al.Core antigen tests for hepatitis C virus:a meta-analysis[J].Mol Biol Rep, 2012, 39 (8) :8197-8208.

[27]WIEGAND J, BUGGISCH P, BOECHER W, et al.Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection:the HEP-NET acute-HCV-II study[J].Hepatology, 2006, 43 (2) :250-256.

[28]KAMAL SM, FOULY AE, KAMEL RR, et al.Peginterferon alfa-2b therapy in acute hepatitis C:impact of onset of therapy on sustained virologic response[J].Gastroenterology, 2006, 130 (3) :632-638.

[29] European Association for the Study of the Liver.EASL clinical practice guidelines:management of hepatitis C virus infection[J].J Hepatol, 2011, 55 (2) :245-264.

[30]DETERDING K, GRUNER NH, BUGGISCH P, et al.Delayed versus immediate treatment for patients with acute hepatitis C:a randomised controlled non-inferiority trial[J].Lancet Infect Dis, 2013, 13 (6) :497-506.

[31]DEUFFIC-BURBAN S, CASTEL H, WIEGAND J, et al.Immediate versus delayed treatmentin patients with acute hepatitis C based on IL28B polymorphism:a modelbased analysis[J].J Hepatol, 2012, 57 (2) :260-266.

[32]CALLERI G, CARITI G, GAIOTTINO F, et al.A short course of pegylated interferon-alpha in acute HCV hepatitis[J].J Viral Hepat, 2007, 14 (2) :116-121.

[33]KAMAL SM, MOUSTAFA KN, CHEN J, et al.Duration of peginterferon therapy in acute hepatitis C:a randomized trial[J].Hepatology, 2006, 43 (5) :923-931.

[34] European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of hepatitis C virus infection[J].J Hepatol, 2014, 60 (2) :392-420.

施引文献

资源附件(0)

访问统计